Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/Phase 2 Open Label Trial of a Novel Indenoisoquinolone C-MYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

NCT07416188 is registered in ClinicalTrials.gov with National Institute of Neurological Disorders and Stroke (NINDS) as lead sponsor.

NCT NCT07416188
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07416188 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/Phase 2 Open Label Trial of a Novel Indenoisoquinolone C-MYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 15, 2026
Completion date
December 31, 2032
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain and central nervous system tumors, brain cancer, gbm, glioblastoma idh (isocitrate dehydrogenase) wildtype, glioblastoma multiforme, glioblastomas, glioma, glioma, malignant, grade iv astrocytoma, high grade glioma, recurrent glioblastoma, recurrent glioma (glioblastoma multiforme), recurrent tumor, recurring glioblastoma, relapsed cancer